Cullen/Frost Bankers, Inc. Roivant Sciences Ltd. Transaction History
Cullen/Frost Bankers, Inc.
- $7.02 Billion
- Q1 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 4,700 shares of ROIV stock, worth $53,815. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,700
Previous 8,300
43.37%
Holding current value
$53,815
Previous $98,000
52.04%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ROIV
# of Institutions
332Shares Held
496MCall Options Held
3.67MPut Options Held
754K-
Qvt Financial LP New York, NY65.8MShares$753 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$708 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$527 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$467 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$411 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.07B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...